OPKO Health (OPK) said Monday it will work with Entera Bio (ENTX) to push an oral dual agonist for obesity and related conditions into clinical testing.
The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.
Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.
To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.
Entera's shares were up more than 10% in recent Monday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。